JHL Biotech Closes $35M Series B Financing

JHL Biotech, Inc., a  Taiwan-based biopharmaceutical company, closed a $35m Series B financing round.

The round was led by new investors Milestone Capital and a consortium of Taiwan venture capitalists and individuals, including President International Development Corp., Fubon Financial Holdings, Taishin Financial Holdings, TaiAn Technologies, Hotung Group, Dr. Allen Chao (founder of Watson Pharmaceuticals), and existing shareholders China Development Industrial Bank, Biomark Capital, and Kleiner Perkins Caufield & Byers.

The company intends to use the funds to develop its biosimilar monoclonal antibody pipeline and accelerate its filing of investigational new drug applications, whilst supporting the ongoing facility expansion in Taiwan and acquiring additional equipment for its commercial manufacturing facility in Wuhan, China, which is expected to be completed by 2014 year-end.

Founded in December 2012 and led by Racho Jordanov, President and CEO, JHL Biotech focuses on bioengineering as well as product development technologies that follow current Good Manufacturing Practices (cGMP). The company has five biosimilar programs and one new molecular entity in development and plans to submit its first clinical trial and investigational new drug applications in 2015.
It completed the construction of its clinical manufacturing facility in Hsinchu, Taiwan in December 2013 and has since formed partnerships with domestic academic and government institutions to discover new molecular entities, as well as with regional and global biotech and pharmaceutical companies to develop oncology and immunology drug candidates.



Join the discussion